<DOC>
	<DOCNO>NCT02096237</DOCNO>
	<brief_summary>In study patient suffer Immunoglobulin E ( IgE ) mediate asthma treat method , call immune apheresis , remove IgE blood . In order achieve blood take continuously patient separate plasma blood cell centrifuge . The plasma pass new IgE adsorber IgE specifically bound . The `` cleaned '' plasma re-joined blood cell give back patient . In total patient randomize apheresis group undergo 3 treatment per week ( i.e . 1 cycle ) every 4 week time period 3 month , mean 9 apheresis treatment 3 cycle total . Study hypothesis new IgE adsorber capable reduce IgE plasma/serum least 50 % measure first treatment first cycle last treatment last treatment cycle . The new adsorber safely use patient . A group patient conventional drug treatment apheresis treatment serf control .</brief_summary>
	<brief_title>Extracorporeal SPecific IgE Removal From Plasma Allergic Asthma Patients ( ESPIRA-study )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Signed Informed Consent Clinically relevant allergy respiratory allergen confirm patient 's history , skinprick testing , IgE serology Allergic asthma ( diagnosed lung specialist ) IgE concentration blood least 300 kilo Units ( kU ) /L Participation another trial within 30 day prior enrolment Gravidity ( pregnancy test prior treatment cycle ) Intake omalizumab Hepatitis HIV malignant disease Specific immunotherapy last 6 month Nonallergic asthma Autoimmune disease Hypocalcaemia Intake ACEinhibitors ( discontinuation accord halftime treatment possible ) Uncontrolled bleed coagulation disorder Severe cardiovascular disease Severe cardiac arrhythmia Severe systemic infection Unability tolerate therapeutic apheresis procedure ( hypersensitivity associate previous apheresis session ) Inadequate peripheral venous access Condition acute fluid shift may cause congestive heart failure Established suspect intracranial disease fluid imbalance pressure change could exacerbate disease Impaired renal function Clinically significant hypotension borderline hypotension drop blood pressure could harmful</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>asthma , bronchial</keyword>
	<keyword>immunoadsorbents</keyword>
	<keyword>apheresis</keyword>
	<keyword>immunoglobulin E</keyword>
</DOC>